Gunderson Dettmer represented biotechnology client RadioMedix, in the announcement of its $40 million equity financing led by Portland Investment Counsel Inc. RadioMedix is a clinical-stage biotech focused on targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The new capital will be used to advance its targeted alpha therapy (TAT) platform and diagnostic radiopharmaceuticals for rare and aggressive cancers.

In the announcement of the transaction, Chairman and Chief Executive Officer of RadioMedix Dr. Ebrahim Delpassand said, “We are living in an exciting time with the treatment of difficult cancers. Targeted radionuclide therapy with beta and alpha emitters and specific radiopharmaceutical diagnostic probes are among the most innovative emerging technologies available to us. This funding will accelerate our efforts to make several of these medications available to our patients.”

The Gunderson Dettmer deal team was led by Wes Watts and included Alex Devine.

Companies:
RadioMedix
Portland Investment Counsel Inc